This is the authors' abstract. We don't add key points for this paper.
At week 52, risankizumab demonstrated superior efficacy and similar safety with less frequent dosing compared with secukinumab.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Warren et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: